A Multicenter, Placebo-controlled Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas：6-year Retrospective Follow-up Data

Colorectal cancer (CRC) is a common malignancy of the digestive tract, which constitutes a major public health burden. Almost 90% of CRC cases progress from precursor adenomatous polyps through adenoma-carcinoma sequence. Endoscopic detection and removal of colorectal adenoma (CRA) could reduce the incidence and mortality risk of CRC, but the recurrence rate is still high. Therefore, chemoprevention is quite important, not only solve the urgent public health problem, but also be cost-effective.
In 2020, the investigators published a multicenter, randomized, double-blind, placebo-controlled clinical study (NCT02226185) in the Lancet Gastroenterology & Hepatology. The result concluded that oral BBR for 2 years significantly reduced recurrence after endoscopic removal of CRA (RR 0.77, 95%CI 0.66-0.91; p=0.001). BBR also has a significant preventive effect on all polypoid lesions, including adenomas and serrated lesions (adjusted RR 0.78, 95%CI 0.66-0.91; p=0.002) . Does BBR still have a long-term protective effect on the recurrence of CRA after discontinuation? That's what the investigators concerned.
The present study is performed to observe and compare retrospectively the recurrence rate of CRAs in patients of the original BBR RCT study (NCT02226185) within 6 years after discontinuation of medication, including the overall recurrence rate of traditional adenomas within the first year, 1-3 years, 3-6 years, and the entire follow-up period of 6 years. The aim is to evaluate the long-term efficacy of BBR in preventing recurrence and carcinogenesis after endoscopic resection of CRAs.

开始日期2024-10-04

申办/合作机构

上海交通大学医学院

[+4]

NCT06530069 / RecruitingN/AIIT

Exploring the Risk Factors of Otomycosis: A Case-Control Study

The goal of this observational study is to explore the risk factors of fungal otitis externa in the fungal otitis externa patients The main question it aims to answer is:
What behaviors lead to the occurrence of fungal otitis externa? Participants will complete a detailed questionnaire survey. If there is a comparison group: Researchers will compare the healthy group and the disease group to see if there are any differences.

开始日期2024-08-01

申办/合作机构

厦门大学附属中山医院

NCT06434649 / RecruitingN/AIIT

Application of the Extra-fascial Robot Assisted Radical Prostatectomy Via the Posterior Approach in Intermediate or High Risk Patients: a Prospective, Multicenter, Double-blind, Randomized Controlled Study

This study was designed as a prospective, multicentre, double-blind, randomised controlled clinical trial. It aims to investigate the feasibility and safety of the posterior approach extrafascial technique and the anterior approach extrafascial technique in robot-assisted radical prostatectomy (RARP) for intermediate- and high-risk prostate cancer patients, to compare the oncological prognosis, functional prognosis, and safety of the two techniques in intermediate- and high-risk prostate cancer patients, and to provide evidence-based medical evidence for the choice of surgical treatment modality for intermediate- and high-risk prostate cancer patients.

开始日期2024-07-01

申办/合作机构

福建医科大学附属第一医院

[+10]

100 项与厦门大学附属中山医院相关的临床结果

登录后查看更多信息

0 项与厦门大学附属中山医院相关的专利（医药）

登录后查看更多信息

928

项与厦门大学附属中山医院相关的文献（医药）

2024-12-31·Hematology

Hub genes and associated drugs for multiple myeloma with 1q21+: identified by bioinformatic analysis

Article

作者: Xu, Zhiqiang ; Chen, Yamei ; Yu, Jieni

While 1q21+ was common genetic alteration and found to have adverse effect on prognosis, the underlying genes remain unclear. Identification of related genes may provide additional help for rational intervention. The microarray dataset GSE2658 associated with MM was downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were obtained, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to annotate their functions. The hub genes were derived from the combined results of up-regulated DEGs and weighted gene coexpression network analysis (WGCNA). The receiver operating characteristic (ROC) curves of hub genes were plotted to evaluate correlation with 1q21+. Survival analysis and drug-gene interaction of hub genes were performed separately to find the prognostic value and potential targeted drugs. A total of 55 DEGs were identified. GO and KEGG pathway analyses suggested that the DEGs were related to several pathways of cell proliferation. NVL, IL6R, DUSP23 were proven to be highly correlated with 1q21+ and have adverse effects on prognosis. IL6R, DUSP23 were matched to known interaction-drug. This study revealed potential roles of hub genes in the pathogenesis and progression of MM with 1q21+, further investigations are needed to elucidate the mechanisms.

2024-12-31·Emerging Microbes & Infections

Treponema pallidum protein Tp0136 promotes angiogenesis to facilitate the dissemination of Treponema pallidum

Article

作者: Li, Qiu-Ling ; Li, Ze ; Zeng, Yan-Li ; Lin, Yu ; Zheng, Xin-Qi ; Yang, Tian-Ci ; Li, Wei ; Luo, Xi ; Meng, Qing-Qi

The incompletely eliminated Treponema pallidum (T. pallidum) during primary syphilis chancre infection can result in the progression of secondary, tertiary, or latent syphilis in individuals, suggesting that T. pallidum has successfully evaded the immune response and spread to distant sites. The mechanism underlying the dissemination of T. pallidum is unclear. Here, a syphilitic rabbit model dorsal-injected with recombinant Tp0136 protein or Tp0136 antibody subcutaneously was used to demonstrate the role of Tp0136 protein in promoting the dissemination of T. pallidum to the testis and angiogenesis in vivo; vascular endothelial cell line HMEC-1 was employed to display that Tp0136 protein enhances the angiogenesis. Furthermore, the three-dimensional microfluidic angiogenesis system showed that the angiogenesis would heighten vascular permeability. Then transcriptome sequencing analysis, in conjunction with cell-level validation, elucidated the critical role of the PI3K-AKT signaling pathway in the promotion of angiogenesis by Tp0136 protein, resulting in heightened permeability. These findings elucidate the strategy employed by T. pallidum in evading immune clearance.

2024-12-31·Virulence

Throat microbiota drives alterations in pulmonary alveolar microbiota in patients with septic ARDS

Article

作者: Liu, Yan-Qi ; Wang, Xi-Bo ; Man, Ming-Yin ; Peng, Ya-Hui ; Zhang, Jian-Nan ; Chong, Yang ; Lv, Jia-Feng ; Luan, Fei-Yu ; Li, Na-Na ; Kang, Kai ; Yu, Kai-Jiang ; Wang, Yi-Qi ; Zhao, Ming-Yan ; Wang, Lei ; Luo, Pei-Yao ; Zhou, Yang ; Zhang, Qian-Qian ; Wang, Chang-Song ; Li, Yue

OBJECTIVESThe translocation of intestinal flora has been linked to the colonization of diverse and heavy lower respiratory flora in patients with septic ARDS, and is considered a critical prognostic factor for patients.METHODSOn the first and third days of ICU admission, BALF, throat swab, and anal swab were collected, resulting in a total of 288 samples. These samples were analyzed using 16S rRNA analysis and the traceability analysis of new generation technology.RESULTSOn the first day, among the top five microbiota species in abundance, four species were found to be identical in BALF and throat samples. Similarly, on the third day, three microbiota species were found to be identical in abundance in both BALF and throat samples. On the first day, 85.16% of microorganisms originated from the throat, 5.79% from the intestines, and 9.05% were unknown. On the third day, 83.52% of microorganisms came from the throat, 4.67% from the intestines, and 11.81% were unknown. Additionally, when regrouping the 46 patients, the results revealed a significant predominance of throat microorganisms in BALF on both the first and third day. Furthermore, as the disease progressed, the proportion of intestinal flora in BALF increased in patients with enterogenic ARDS.CONCLUSIONSIn patients with septic ARDS, the main source of lung microbiota is primarily from the throat. Furthermore, the dynamic trend of the microbiota on the first and third day is essentially consistent.It is important to note that the origin of the intestinal flora does not exclude the possibility of its origin from the throat.

项与厦门大学附属中山医院相关的新闻（医药）

2024-10-29

·华森制药

华森制药携甘桔冰梅片参加2024年广东省中西医结合学会嗓音专业委员会学术大会

为了进一步促进广东省中医、中西医结合嗓音专业的发展，提高省内嗓音专业中医、中西医结合学术水平。2024年10月25-27日，广东省中西医结合学会嗓音专业委员会换届大会、学术年会暨广东省名中医李云英教授学术思想传承学习班在广东中山市召开。同期举办了言语与听力论坛、中西医结合治疗内耳疾病理论创新与特色技术培训班。身为东道主的中山市中医院党委书记赖海标进行了开幕欢迎致辞并对中山市中医院的近几的发展成果和未来几年的规划做了汇报。广东省中医院、广东省中西医结合嗓音专业委员会主任委员李云英主委进行了开幕致辞广东省中医院、广东省中西医结合嗓音专业委员会副主任委员陈文勇主委进行了开幕致辞会议邀请了国内中西医领域的32位知名专家授课，就嗓音医学、听力言语医学的最新研究进展、行业前景、中西医结合治疗嗓音与听力言语疾病的经验分享等进行阐述，共同探讨嗓音、听力言语健康与疾病防治的最新研究成果与临床应用。大会分为主会场、护理专场、言语听力专场。本次会议以权威讲座、学术交流、实操工坊相结合的方式进行，会议议程涵盖了嗓音医学、听力言语疾病的基础研究、中西医临床诊断与治疗技术、嗓音言语康复、嗓音耳部疾患保护等多个方面。会议吸引了超过400余名专业人士参与，会场热烈和谐、精彩纷呈，与会者普遍认为本次会议内容丰富、形式多样，对嗓音医学领域的研究与临床实践具有重要的指导意义。厦门大学附属中山医院庄佩耘教授作《嗓音疾病的诊疗原则及嗓音医学的前景》学术报告河南中医药大学第一附属医院梅祥胜教授作《钢琴在嗓音病诊疗中的应用》学术报告深圳市中医院刘元献教授作《咽喉疾病的经方应用初探、耳鸣耳聋--如何辩证使用中成药》报告广东省中医院(总院)耳鼻咽喉头颈科主任朱任良教授作《皮瓣在耳鼻咽喉头颈手术修复的应用》报告本次嗓音学术会议的成功举办，为嗓音医学、听力言语疾病领域的专家学者提供了一个高水平的学术交流平台，促进了嗓音医学、听力言语疾病研究与临床实践的深入发展。华森制药携甘桔冰梅片、苍耳子鼻炎胶囊等产品参加了本次会议，同与会专家进行了产品的介绍和交流，获得了专家的认可。甘桔冰梅片为耳鼻喉专科特色产品，由甘草、桔梗、冰片、乌梅等八味中药组成，具有清热解毒、消肿止痛、宣肺化痰、生津润燥的功效，治疗咽喉疾病可抗炎镇痛、抗菌、抗病毒、止咳化痰、抗变态反应，有效缓解咽痛、声音嘶哑、咽干灼热、咽黏膜充血等问题。被纳入多项临床诊疗指南/专家共识推荐用药，并入选国家《100个基于评价证据疗效独特的中药品种》。

高管变更

2024-10-28

·PRNewswire

MitrAssist Lifesciences Announces Promising Initial Clinical Results for SIKELIA™ Polymeric Heart Valve at TCT Conference 2024

WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA™, during the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C. The early findings demonstrate promising potential in improving outcomes for patients suffering from severe symptomatic aortic stenosis. SIKELIA transthoracic heart valve (THV) is designed for transcatheter aortic valve implantation (TAVI) procedure. It features a unique polymer leaflet design which allows enhanced durability and reduced thrombogenicity and calcification while lowering production costs. SIKELIA THV is also fully retrievable at 100% frame expansion allowing reposition in case of misplacement. The clinical trial results, involving 12 patients from 4 centers, with a maximum follow up of 27 months, revealed favorable safety and performance 1-year outcomes. A significant improvement in hemodynamic performance was demonstrated by reduced mean pressure gradient and increased effective orifice area. The functional status as assessed by NYHA class, 6-minute walk test and KCCQ score was improved significantly in all measures. In addition, at 1 year follow-up, normal leaflet mobility without hypoattenuated leaflet thickening (HALT) or calcification was confirmed in all patients. "The initial clinical results of SIKELIA™ mark a significant milestone in our mission to transform patient care," said Peggy Wang, CEO of MitrAssist. "We are excited about the potential SIKELIA has to improve outcomes for patients suffering from severe aortic stenosis. SIKELIA capabilities and these initial results provide a foundation for the next phases of clinical testing, and we look forward to continuing our work to bring this innovation to physicians and patients around the world." The presentation at the TCT Conference attracted the attention of top physicians, industry leaders and medical professionals eager to explore more about the product. Dr. Xiaochun Zhang from Zhongshan Hospital and the Shanghai Medical College of Fudan University presented the initial results of this first-in-human, prospective, single-arm, multicenter study, on behalf of the study investigators. In addition to Zhongshan Hospital, the participating centers included Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Xiamen Cardiovascular Hospital Xiamen University and Zibo Central Hospital. "The initial outcomes we are seeing from SIKELIA™ could represent a real breakthrough in the TAVR field," said Prof. Junbo Ge from Zhongshan Hospital, principal investigator of the clinical trial. "The potential for improving patients' outcomes is immense, and we are eager to continue gathering data and enhancing the application of this technology. These results are just the beginning, and they pave the way for more comprehensive studies in the near future." For further information, please visit MITRASSIST LIFESCIENCES LIMITED is a leading global company for innovative cardiovascular medical devices, focusing on providing advanced diagnostic and therapeutic solutions for cardiovascular patients. The company product line covers a wide range of applications in the cardiovascular field from structural heart disease to heart failure. MitrAssist is dedicated and committed to innovation and improving patient care. Logo: SOURCE MitrAssist Lifesciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果AHA会议

2024-07-17

·赛柏蓝

国家检查组进驻！严查医院

作者 | 颜色陈芋来源 | 赛柏蓝全国医院大检查密集开展，典型问题一一曝光。 01 国家飞检点名7大重点问题差异化省级飞检同步推进日前，国家医保基金飞检组第11省启动会召开，自今年5月国家医保局联合财政部、国家卫健委、国家中医药局启动现场检查以来，安徽、山西、云南、湖南、四川、山东、浙江、吉林、辽宁、海南、河南的国家飞检均已展开。国家飞行检查组“点对点”开展检查的同时，北京、广西等国家飞行检查组暂未空降的省份，以及山西等已完成国家飞检的省份省级飞检拉开，检查重点也与国家组形成差异。以山西为例，7月15日，山西省级飞检启动会在太原召开，飞检覆盖2022年-2023年医保基金使用、管理及有关内控制度建设、实施情况，聚焦麻醉、肺部肿瘤用药、重症监护三个方面。按计划，省级飞检组将抽签对太原的1家省属定点公立医院、1家太原市定点公立医院、1家定点民营医院、1家门诊医疗机构、1家定点零售药店进行现场检查。今年，国家医保局对飞检结果的跟进更加迅速，目前已有多家在飞检中被发现存在欺诈骗保问题的医院被点名，“边查边通报”的形式也在一定程度上形成更强震慑。本月中旬，国家医保局发布《定点医疗机构违法违规使用医疗保障基金典型问题清单（2024版）》（以下简称《问题清单》），对7类违规问题划出重点。据赛柏蓝梳理，《问题清单》主要点名串换项目、分解收费、超标准收费、重复收费、过度检查、虚构医药服务项目、将不属于医保支付范围的纳入医保基金结算等7类违规问题。从近年来飞行检查情况看，定点医药机构重复收费、超标准收费、分解项目收费约占所有违法违规使用医保基金问题的36%；串换药品、医用耗材、诊疗项目和服务设施约占17%；违反诊疗规范过度诊疗、过度检查，提供其他不必要的医药服务约占14%；将不属于医保基金支付范围的医药费用纳入医保基金结算约占14%。另外，医保基金使用金额大、存在异常变化的药品耗材大概率也是今年医保基金监管的工作重点。在国家医保局、最高检、公安部、财政部、国家卫健委联合印发《2023年医保领域打击欺诈骗保专项整治工作方案》中，人血白蛋白、贝伐珠单抗、安宫牛黄丸、通心络片（胶囊）等120个医保结算费用排名靠前的药品、耗材均已作为重点对象被纳入监管范围。 02 大型医院巡查16省启动从省级向市级延伸国家医保飞检现场检查，同时通报医院违规使用医保基金典型问题。与此同时，大型医院巡查已经在16省启动。截至7月17日，据赛柏蓝不完全统计，上海、福建、江苏、贵州、海南、河南、黑龙江、甘肃、青海、内蒙古、天津、广东、湖南、山东、河北、四川均已发布大型医院巡查方案。与以往不同的是，大型医院的巡查开始向市级“进发”。日前，厦门市卫健委发布《厦门市大型医院巡查工作方案（2024-2026年度）的通知》，巡查自本月（7月）启动，2026年9月底完成本轮巡查。值得注意的是，厦门市公布了具体的市卫健委巡查工作小组名单以及市级医院巡查名单、时间安排。2024-2026年拟巡查17家大医院，包括厦门大学附属第一医院、厦门大学附属中山医院等大三甲（详见文末）。截至目前，已经有5个省份公布了将接受巡查的医院名单，分别是四川（13家）、甘肃（12家）、黑龙江（24家）、江苏（17家）、福建（14家）。大型医院巡查原则上对二级（参照二级管理）及以上公立医院（含中医医院）进行巡查，社会办医院按照管理原则参照执行。针对三级综合医院巡查时间原则上不少于7天，三级专科医院、妇幼保健院和二级医院原则上不少于5天。多地大型医院巡查要求加强对“关键少数”、关键岗位的监督，建立完善覆盖重点岗位、重点人员、重点医疗行为、重要药品耗材、大型医疗设备等监管机制。紧盯“关键少数”，加强“渗透式”监管。从各地落实的进度看，多部门均在行动。不完全统计，仅在今年上半年，中纪委已经在7篇文章点名相关医院或该院的管理人员。此外，各地医院纷纷落实医药代表院内拜访制度。与此同时，不少省份的大型医院巡查内容提到，建立内部审计、纪检监察贯通协同机制，更好发挥审计监督作用。据赛柏蓝不完全统计，今年来，内蒙古、福建、江苏、浙江、北京、安徽、重庆、山东、宁夏等多个省份审计部门均在医疗反腐领域开展相关工作，重点关注公立医院在药品、医用耗材和设备采购使用环节以及医疗收费等方面存在的突出问题。新一轮大型医院巡查工作自2023年12月18日，国家卫健委办公厅发布《大型医院巡查工作方案（2023-2026年度）》开始，于2026年10月底前完成本轮巡查。截至目前，全国31个省、直辖市、自治区（不含港澳台），目前还有15个省份暂未公布大型医院巡查方案。大型公立医院逐渐带上“紧箍咒”。各地拟医院巡查名单及时间安排 END 内容沟通：郑瑶（13810174402）医药代理商产品交流群扫描下方二维码加入医药代表交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

100 项与厦门大学附属中山医院相关的药物交易

登录后查看更多信息

100 项与厦门大学附属中山医院相关的转化医学

登录后查看更多信息